{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:22:06Z","timestamp":1783074126876,"version":"3.54.6"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"internal funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Favipiravir (T-705) shows potent in vitro activity but inconsistent in vivo efficacy. We assessed how plasma exposure and tissue distribution shape antiviral coverage using a tissue-based PK\/PD framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Favipiravir and its hydroxylated metabolite (M1) were quantified in plasma and multiple organs of Syrian golden hamsters after single and repeated dosing and compared with a non-human primate dataset. We derived tissue penetration factors (TPFs), metabolic ratios (MR) and inhibitory quotients (IQ) against published EC50 values for representative RNA viruses and integrated these results with available human pharmacokinetic data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Favipiravir absorbed rapidly and distributed heterogeneously, reaching highest levels in kidney, gut and respiratory organs with limited brain access; M1 was enriched in liver and kidney. Organ exposure ranking was broadly similar across species. Tissue IQs were often lower than plasma IQs, indicating that plasma monitoring can overestimate target-organ coverage. IQ analysis suggested favourable coverage for influenza and RSV, heterogeneous, dose-dependent coverage for chikungunya, Rift Valley fever viruses and Orthohantavirus andesense (ANDV), intermediate coverage for Zika virus, and limited coverage for SARS-CoV-2, ebolavirus and West Nile virus. For some viruses, coverage may require higher exposures, prompting dose reassessment and safety data. The IQ patterns aligned with reported preclinical efficacy, and human pharmacokinetics suggested robust exposure margins for influenza but insufficient margins for SARS-CoV-2 and ebolavirus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tissue-based IQs refine the interpretation of exposure\u2013response relationships and help explain favipiravir\u2019s variable in vivo performance. The same framework can be refined and applied to other antiviral candidates to support preparedness strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag224","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:19:08Z","timestamp":1781695148000},"source":"Crossref","is-referenced-by-count":0,"title":["Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4743-3626","authenticated-orcid":false,"given":"Paul-R\u00e9mi","family":"Petit","sequence":"first","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-2249","authenticated-orcid":false,"given":"Franck","family":"Touret","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-2938","authenticated-orcid":false,"given":"Jean-S\u00e9lim","family":"Driouich","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8898-6702","authenticated-orcid":false,"given":"Albert","family":"Par\u00e9","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Toxicologie Exp\u00e9rimentAle et Mod\u00e9lisation, INERIS, Institut National de L\u2019Environnement Industriel et des Risques , Verneuil-en-Halatte 60550 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-2720","authenticated-orcid":false,"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-0171","authenticated-orcid":false,"given":"Romain","family":"Marlin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases \u00bb (IMVA-HB\/IDMIT) , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-9819","authenticated-orcid":false,"given":"Vanessa","family":"Contreras","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases \u00bb (IMVA-HB\/IDMIT) , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-8481","authenticated-orcid":false,"given":"Francis","family":"Relouzat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases \u00bb (IMVA-HB\/IDMIT) , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-3454","authenticated-orcid":false,"given":"Anne-Sophie","family":"Gallou\u00ebt","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases \u00bb (IMVA-HB\/IDMIT) , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-7080","authenticated-orcid":false,"given":"Quentin","family":"Pascal","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases \u00bb (IMVA-HB\/IDMIT) , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM, IAME , Paris F-75018 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4928-4484","authenticated-orcid":false,"given":"Roger","family":"Le Grand","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases \u00bb (IMVA-HB\/IDMIT) , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-2636","authenticated-orcid":false,"given":"Antoine","family":"Nougair\u00e8de","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-9648","authenticated-orcid":false,"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille 13005 ,","place":["France"]},{"name":"Laboratoire de Pharmacocin\u00e9tique et Toxicologie, H\u00f4pital La Timone, APHM , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026070306001141300_dkag224-B1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"2026070306001141300_dkag224-B2","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070306001141300_dkag224-B3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3851\/IMP3180","article-title":"In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin","volume":"22","author":"Baz","year":"2017","journal-title":"Antiviral Ther"},{"key":"2026070306001141300_dkag224-B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.02.005","article-title":"Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice","volume":"545","author":"Fang","year":"2020","journal-title":"Virology"},{"key":"2026070306001141300_dkag224-B5","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a new ribonucleoside inhibitor of Ebola virus replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"2026070306001141300_dkag224-B6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of favipiravir to treat Lassa virus infection in macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2026070306001141300_dkag224-B7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070306001141300_dkag224-B8","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1038\/s41467-022-32565-w","article-title":"Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates","volume":"13","author":"Marlin","year":"2022","journal-title":"Nat Commun"},{"key":"2026070306001141300_dkag224-B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"2026070306001141300_dkag224-B10","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5689","article-title":"Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC\u2013MS\/MS method","volume":"37","author":"Bekegnran","year":"2023","journal-title":"Biomed Chromatogr"},{"key":"2026070306001141300_dkag224-B11","author":"Baumgartner"},{"key":"2026070306001141300_dkag224-B12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41598-018-37866-z","article-title":"Synthesis of [18F]favipiravir and biodistribution in C3H\/HeN mice as assessed by positron emission tomography","volume":"9","author":"Bocan","year":"2019","journal-title":"Sci Rep"},{"key":"2026070306001141300_dkag224-B13","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1007\/s00415-020-09866-5","article-title":"CNS penetration of potential anti-COVID-19 drugs","volume":"267","author":"Richardson","year":"2020","journal-title":"J Neurol"},{"key":"2026070306001141300_dkag224-B14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/ph16040524","article-title":"Evaluation of [18F]favipiravir in rodents and nonhuman primates (NHP) with positron emission tomography","volume":"16","author":"Rong","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026070306001141300_dkag224-B15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/bdd.2275","article-title":"Favipiravir biotransformation in liver cytosol: species and sex differences in humans, monkeys, rats, and mice","volume":"42","author":"Hanioka","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"2026070306001141300_dkag224-B16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/jps.2600751104","article-title":"Man versus beast: pharmacokinetic scaling in mammals","volume":"75","author":"Mordenti","year":"1986","journal-title":"J Pharm Sci"},{"key":"2026070306001141300_dkag224-B17","author":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA)"},{"key":"2026070306001141300_dkag224-B18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070306001141300_dkag224-B19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/095632020301400502","article-title":"In vitro and in vivo activities of T-705 and oseltamivir against influenza virus","volume":"14","author":"Takahashi","year":"2003","journal-title":"Antivir Chem Chemother"},{"key":"2026070306001141300_dkag224-B20","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials","volume":"226","author":"Hayden","year":"2022","journal-title":"J Infect Dis"},{"key":"2026070306001141300_dkag224-B21","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1093\/infdis\/jiad409","article-title":"Oral favipiravir exposure and pharmacodynamic effects in adult outpatients with acute influenza","volume":"230","author":"Hayden","year":"2024","journal-title":"J Infect Dis"},{"key":"2026070306001141300_dkag224-B22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.antiviral.2017.09.016","article-title":"Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection","volume":"149","author":"Abdelnabi","year":"2018","journal-title":"Antiviral Res"},{"key":"2026070306001141300_dkag224-B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002790","article-title":"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational rift valley fever","volume":"8","author":"Caroline","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2026070306001141300_dkag224-B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104904","article-title":"Strain-dependent disease and response to favipiravir treatment in mice infected with chikungunya virus","volume":"182","author":"Julander","year":"2020","journal-title":"Antiviral Res"},{"key":"2026070306001141300_dkag224-B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116722","article-title":"Rift valley fever virus infection in Golden Syrian Hamsters","volume":"10","author":"Scharton","year":"2015","journal-title":"PLoS One"},{"key":"2026070306001141300_dkag224-B26","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070306001141300_dkag224-B27","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat Commun"},{"key":"2026070306001141300_dkag224-B28","doi-asserted-by":"publisher","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2\u2212infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070306001141300_dkag224-B29","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1111\/bcp.15227","article-title":"Pharmacokinetic characterization of favipiravir in patients with COVID-19","volume":"88","author":"G\u00fclhan","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026070306001141300_dkag224-B30","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/cpt.70261","article-title":"Optimal dose and safety of intravenous favipiravir in hospitalized patients with COVID -19: a dose-escalating, randomized controlled phase Ib study","volume":"119","author":"Rowland","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"2026070306001141300_dkag224-B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2026070306001141300_dkag224-B32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antiviral Res"},{"key":"2026070306001141300_dkag224-B33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2015.07.003","article-title":"Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever","volume":"121","author":"Gowen","year":"2015","journal-title":"Antiviral Res"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag224\/68689777\/dkag224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag224\/68689777\/dkag224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:01:35Z","timestamp":1783072895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag224\/8724032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag224","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dkag224"}}